key: cord-1056590-80beo6na
authors: Schmidle, P; Biedermann, T; Posch, C
title: COVID‐19 in a melanoma patient under treatment with checkpoint‐inhibition
date: 2020-05-26
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16661
sha: 14a7685602d7e8fec8793ac2ea19ccabd42b515f
doc_id: 1056590
cord_uid: 80beo6na

SARS‐CoV‐2 poses new challenges in all aspects of healthcare. Patients with preexisting cardio‐vascular conditions are at higher risk of developing severe symptoms and worse outcome. Data also suggest that cancer patients are particularly vulnerable, but differences between tumor entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID‐19.

cardio-vascular conditions are at higher risk of developing severe symptoms and worse outcome [2] . Data also suggest that cancer patients are particularly vulnerable [2, 3], but differences between tumor entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID-19.

We present the case of a 47-year-old female contracting COVID-19 while being under adjuvant immunotherapy with the PD1-antagonist nivolumab for fully resected stage IV melanoma. The 

This article is protected by copyright. All rights reserved

The patient did not develop any severe respiratory symptoms like dyspnea or drop in oxygen saturation throughout the course of the disease; fever resolved spontaneously within 3 days. No treatment for COVID-19 was required, however, checkpoint-inhibition was paused as a precautionary measure [4] . Two weeks after the first onset of COVID-19 symptoms SARS-CoV-2-IgG antibodies were detected suggesting at least partial immunity. Extensive laboratory tests, including analyses of T-cell sub-populations were all within normal range. A thoracic CT scan 3 weeks after onset of symptoms did not show any lung pathologies nor immune-therapy associated alterations.

Checkpoint inhibition (CPI) has revolutionized melanoma treatment by reengaging exhausted Tcells boosting cancer cell elimination. Yet, CPI is a two edged sword: while the reactivation of anti-tumor immunity has proved successful therapeutically, immune-related adverse events (irAE) particularly CPI-induced pneumonitis may be life threatening. Similarly, a well-orchestrated and balanced T-cell response most likely determines the course of viral infections including COVID-19 [5] . First data indicates that persisting viral infections cause T-cell cytopenia and the exhaustion of T-cells responsible for the development of more severe symptoms [6] . It remains an open question, however, if checkpoint blockade may positively affect COVID-19 disease course leading to a stronger anti-viral, adaptive immune response, or on the contrary may cause a proinflammatory phenotype leading to access tissue damage [6, 7] .

Our melanoma patient receiving adjuvant PD-1 treatment had mild to moderate COVID-19 symptoms, has now fully recovered and remains tumor free. 

Skin cancer triage and management during COVID-19 pandemic

The many faces of the anti-COVID immune response. The Journal of experimental medicine

CoViD-19 Immunopathology and Immunotherapy

Controversies about COVID-19 and anticancer treatment with immune